Related party transactions

Related party transactions

On 6 April 2017, the acceptance of the 150,000 warrants offered on 20 January 2017 to our new Chief Medical Officer, Walid Abi-Saab, under Warrant Plan 2016 (B) was enacted. These warrants have a term of eight years as of the date of the offer. The exercise price of the warrants is €62.50. Each warrant gives the right to subscribe for one new Galapagos share. The warrants vest only and fully on the third anniversary of the notary deed enacting the acceptance of the warrants. The warrants are not transferable and can in principle not be exercised prior to 6 April 2020.

On 17 May 2017, the members of the board of directors and the executive committee were offered new warrants under Warrant Plan 2017, subject to acceptance. As of the date of this report, the acceptance period for Warrant Plan 2017 is still ongoing, so the final number of warrants granted to members of the board of directors and the executive committee cannot be determined yet. Under Warrant Plan 2017, the warrants have an exercise term of eight years as of the date of the offer. The exercise price of the warrants is €80.57. Each warrant gives the right to subscribe for one new Galapagos share. As regards the directors, the warrants vest over a period of 36 months at a rate of 1/36th per month. As regards the other beneficiaries, the warrants vest only and fully on the first day of the fourth calendar year following the calendar year in which the grant was made. The warrants are not transferable and can in principle not be exercised prior to 1 January 2021.

The table below sets forth the number of warrants offered under Warrant Plan 2017 to each member of the board and executive committee in office during the first six months of 2017:

Name

Title

Number of 2017
Warrants offered

Onno van de Stolpe

Chief Executive Officer; Executive director

100,000

Raj Parekh

Non-executive director; Chairman of the board

15,000

Werner Cautreels

Non-executive director

7,500

Harrold van Barlingen

Non-executive director

7,500

Howard Rowe

Non-executive director

7,500

Katrine Bosley

Non-executive director

7,500

Christine Mummery

Non-executive director

7,500

Mary Kerr

Non-executive director

7,500

Piet Wigerinck

Chief Scientific Officer

60,000

Bart Filius

Chief Financial Officer

60,000

Andre Hoekema

Senior Vice President Corporate Development

60,000

Walid Abi-Saab

Chief Medical Officer

45,000

During the first six months of 2017, there were no changes to related party transactions disclosed in the 2016 annual report that potentially had a material impact on the financials of the first six months of 2017.